CHE Stock Recent News
CHE LATEST HEADLINES
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Chemed (CHE) came out with quarterly earnings of $5.20 per share, missing the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.82 per share a year ago.
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 2024, at approximately 12:00 p.m. (ET). The virtual presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be ac.
Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare (ADUS) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemed (CHE) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $6.25 per share. This compares to earnings of $5.39 per share a year ago.